Co-founded by UPenn’s Wilson, Passage Bio outlines clinical goals in new IPO filing

Less than a year after emerging from stealth mode, gene therapy company Passage Bio revealed new details about its pipeline and clinical timelines through the filing of a prospectus for its planned IPO.

Founded in July 2017, Passage Bio Inc. is building a pipeline of programs via a research collaboration with the University

Read the full 522 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers